Indication
Marginal Zone B Cell Lymphoma
1 clinical trial
3 products
Product
ZanubrutinibClinical trial
A Three-Arm Study of ME-401 Monotherapy in Subjects With Relapsed/Refractory CLL, SLL, or FL, of ME-401 in Combination With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination With Zanubrutinib in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHLStatus: Terminated, Estimated PCD: 2023-03-29
Product
ME-401Product
Rituximab